ISSN : 2347-2251

Indo-American Journal of Pharma and Bio Sciences



iajpb.editor@gmail.com
editor@iajpb.com

www.iajpb.com

ISSN 2347-2251
www.iajpb.org
Indo-Am. J. Pharm & Bio.Sc.,2026
Vol. 24, Issue 1, 2026
Indo-American Journal of Pharma and Bio Sciences

GOUT – A NARRATIVE REVIEW

Dr. H. Venkatesan*, Dr. Andalamala Nagasri

Vinayaka Mission's Homoeopathic Medical College & Hospital, Salem (VMRFDU)

Emai: *venkathompath@gmail.com

Introduction and Definition

Gout is a chronic crystal-induced inflammatory arthritis caused by the deposition of monosodium urate (MSU) crystals in joints and periarticular tissues as a result of persistent hyperuricemia [1,2]. It is one of the most common forms of the inflammatory arthritis worldwide and has been recognized since ancient times, with descriptions dating back to Hippocrates [3]. Hyperuricemia is defined as a serum urate concentration exceeding the physiological saturation threshold of approximately 6.8 mg/dL, above which urate precipitates as crystals [4]. However, not all individuals with hyperuricemia develop gout [5]. Historically, gout was referred to as the "disease of kings" because of its association with excessive consumption of rich foods and alcohol. However, contemporary evidence indicates that gout is primarily a metabolic disorder with strong links to impaired renal urate excretion, obesity, insulin resistance, hypertension, chronic kidney disease, and cardiovascular disorders [3]. These associations underscore the systemic nature of gout and its close relationship with modern lifestyle-related diseases.

Epidemiology

Gout affects approximately 1–2% of the adult population in developed countries, with prevalence steadily increasing over recent decades [6]. The disease predominantly affects men, with a male-to-female ratio of approximately 5–10:1, although incidence in women rises after menopause due to loss of estrogen's uricosuric effect [1,7]. The prevalence increases with advancing age, obesity, alcohol intake, and dietary factors rich in purines [6,8]. Gout is also strongly associated with comorbid conditions such as hypertension, chronic kidney disease, metabolic syndrome, and cardiovascular disease [6,9].

Pathophysiology of Gout

The pathophysiology of gout is centered on chronic hyperuricemia and the subsequent deposition of monosodium urate (MSU) crystals, which initiate and sustain inflammatory responses in joints and other tissues [1,2]. Gout represents a prototypical example of crystal-

ISSN 2347-2251
www.iajpb.org
Vol. 24, Issue 1, 2026

induced inflammation, involving complex interactions between metabolic disturbances, crystal formation, and innate immune activation [6].

Hyperuricemia and Uric Acid Metabolism

Uric acid is the final product of purine metabolism in humans. Unlike most mammals, humans lack the enzyme uricase, which converts uric acid into the more soluble compound allantoin, resulting in higher physiological serum urate levels [5]. Hyperuricemia is generally defined as a serum urate concentration exceeding 6.8 mg/dL, the saturation Point at physiological pH and temperature, beyond which urate precipitates as crystals.

Hyperuricemia arises due to either overproduction of uric acid or, more commonly, underexcretion by the kidneys, with renal urate underexcretion accounting for approximately 90% of cases [7]. Factors contributing to impaired urate excretion include genetic polymorphisms affecting renal urate transporters (such as URAT1 and GLUT9), chronic kidney disease, diuretic use, insulin resistance, and metabolic syndrome [8].

Crystal Formation and Deposition

When serum urate levels remain persistently elevated, MSU crystals form and deposit preferentially in peripheral joints, where lower temperature, reduced blood flow, and mechanical stress favor crystallization [1,3]. The first metatarsophalangeal joint is particularly susceptible, explaining its classic involvement in acute gouty attacks (podagra) [2]. MSU crystals may also deposit in cartilage, synovial membranes, bursae, tendons, and subcutaneous tissues, leading to widespread tissue involvement [4].

Innate Immune Activation and Acute Inflammation

The hallmark of acute gouty arthritis is the intense inflammatory response triggered by MSU crystals. Upon crystal deposition, resident macrophages phagocytose MSU crystals, leading to activation of the NLRP3 inflammasome, a key component of innate immunity [11]. This activation results in cleavage of pro-interleukin-1β (IL-1β) into its active form, which plays a central role in initiating and amplifying inflammation [9,11].

IL-1β promotes the release of additional pro-inflammatory mediators, including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and chemokines, which recruit neutrophils into the joint space [6,9]. Neutrophils ingest MSU crystals and release proteolytic enzymes,

ISSN 2347-2251
www.iajpb.org
Vol. 24, Issue 1, 2026

reactive oxygen species, and inflammatory mediators, producing the characteristic severe pain, erythema, swelling, and warmth seen during acute gout attacks [10].

Resolution of Acute Attacks

Despite the intensity of inflammation, acute gout attacks are self-limiting. Resolution occurs through multiple mechanisms, including clearance of MSU crystals, apoptosis of neutrophils, release of anti-inflammatory cytokines such as interleukin-10, and coating of crystals with serum proteins that reduce their inflammatory potential [13]. However, crystal deposition persists even during asymptomatic periods, allowing disease progression if hyperuricemia remains untreated.

Chronic Inflammation and Tophus Formation

Repeated acute attacks or sustained crystal burden leads to chronic gouty inflammation. Persistent MSU crystal deposition induces a granulomatous foreign-body reaction characterized by macrophages, multinucleated giant cells, fibroblasts, and lymphocytes [1,4]. This process results in the formation of tophi, which are organized aggregates of MSU crystals surrounded by inflammatory tissue [2]. Tophi cause progressive cartilage destruction, bone erosion, and joint deformity by stimulating osteoclast activity and inhibiting osteoblast function. Chronic synovitis and structural damage ultimately lead to reduced joint mobility and functional impairment [7].

Renal and Systemic Effects

MSU crystal deposition is not confined to joints. In the kidneys, urate crystal precipitation can result in uric acid nephrolithiasis and chronic urate nephropathy, further impairing renal function and exacerbating hyperuricemia [5]. Additionally, hyperuricemia and gout are associated with endothelial dysfunction, oxidative stress, and low-grade systemic inflammation, contributing to increased risk of cardiovascular disease and metabolic disorders.

Clinical Features

Gout typically progresses through four clinical stages :

1. **Asymptomatic hyperuricemia** – elevated serum urate without clinical symptoms [5].
2. **Acute gouty arthritis** – sudden onset of severe pain, erythema, swelling, and warmth, often involving a single joint (classically podagra) [2,12].

ISSN 2347-2251
www.iajpb.org
Vol. 24, Issue 1, 2026

3. **Intercritical period** – symptom-free interval between attacks, during which crystal deposition continues [4].
4. **Chronic tophaceous gout** – characterized by persistent arthritis, joint deformity, and visible or palpable tophi in joints, cartilage, bursae, and soft tissues [1,13].

Complications

Repeated acute attacks and untreated hyperuricemia can lead to chronic joint destruction, reduced mobility, and disability [1]. Tophi may cause joint deformities, nerve compression, and skin ulceration [13]. Renal complications include uric acid nephrolithiasis and chronic urate nephropathy, contributing to progressive renal impairment [10,14]. Additionally, gout is independently associated with increased cardiovascular morbidity and mortality, emphasizing its systemic impact [6,9].

Homoeopathic Management of Gout

Homoeopathy approaches gout as a constitutional and metabolic disorder rather than merely a local joint disease. The homoeopathic management of gout is based on the principles of individualization, totality of symptoms, and constitutional prescribing, with the aim of reducing the frequency and intensity of acute attacks, preventing complications, and improving the patient's overall health status [15,16]. Unlike conventional therapy, which primarily targets serum uric acid levels and acute inflammation, homoeopathy seeks to address the underlying predisposition to hyperuricemia and altered metabolic balance [17].

Therapeutic Principles

According to homoeopathic philosophy, gout results from disturbances in the vital force leading to abnormal metabolic processes and accumulation of morbid material, particularly uric acid, in the body [18]. Treatment is therefore directed toward:

- Correction of the underlying constitutional susceptibility
- Regulation of metabolism and elimination
- Relief of acute inflammatory symptoms
- Prevention of chronic joint damage and tophus formation [19]

Homoeopathic medicines are selected based on the individual symptom profile, including the nature of joint pain, modalities (aggravating and ameliorating factors), mental and emotional characteristics, and associated systemic symptoms [20].

ISSN 2347-2251
www.iajpb.org
Vol. 24, Issue 1, 2026
Indo-American Journal of Pharma and Bio Sciences

Homoeopathic Remedies Commonly Used in Gout

Colchicum autumnale

Colchicum is one of the most frequently indicated remedies in acute gout, especially when pain is severe, tearing, and aggravated by the slightest movement or touch [21]. The joints are extremely sensitive, & the pain is often worse at night and during cold weather. It is particularly indicated when gastrointestinal symptoms such as nausea and intolerance to the smell of food accompany joint pain.

Ledum palustre

Ledum is classically indicated in gout beginning in the lower extremities, particularly the feet and toes, and progressing upward [20]. The affected joints are cold to touch but feel better from cold applications, a characteristic modality of this remedy. It is also useful in chronic gout with nodosities around the joints.

Benzoic acid

Benzoic acid is indicated in gout associated with marked urinary abnormalities, particularly strong-smelling urine and a tendency to uric acid deposition [19]. It is considered useful in cases where gout alternates with urinary symptoms [15].

Urtica urens

Urtica urens is used in gout associated with elevated serum uric acid levels, especially when there is burning pain in the joints and associated skin symptoms such as urticaria. It is also recommended as an adjunct in cases with a history of suppressed eruptions [22].

Formica rufa

Formica rufa is frequently indicated in chronic gout and rheumatic conditions with stiffness, swelling, and nodular deposits around joints [23]. It is considered particularly useful in elderly patients with long-standing gout and restricted joint mobility [24]

Lycopodium clavatum

Lycopodium is a constitutional remedy often indicated in gout associated with digestive disturbances, hepatic dysfunction, and right-sided complaints [18]. Symptoms are typically worse between 4–8 PM, and patients may exhibit aggravation from cold drinks and improvement from warm food.

Natrum muriaticum

Natrum muriaticum is useful in gouty patients with a history of suppressed emotions, particularly grief or long-standing stress, along with dryness of mucous membranes and aggravation from heat [20].

ISSN 2347-2251
www.iajpb.org

Vol. 24, Issue 1, 2026

REFERENCES

1. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388(10055):2039–2052.
2. Richette P, Bardin T. Gout. Lancet. 2010;375(9711):318–328.
3. Neogi T. Gout. Ann Intern Med. 2016;165(1):ITC1–ITC16.
4. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005;143(7):499–516.
5. Becker MA, Jolly M. Clinical gout and hyperuricemia. In: Kelley and Firestein's Textbook of Rheumatology. 10th ed. Elsevier; 2017. p. 1527–1552.
6. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout. Nat Rev Rheumatol. 2015;11(11):649–662.
7. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia. Arthritis Rheum. 2011;63(10):3136–3141.
8. Doghramji PP, Wortmann RL. Hyperuricemia & gout. Postgrad Med. 2012;124(6):98–109.
9. Ragab G, Elshahaly M, Bardin T. Gout: An old disease in new perspective. J Adv Res. 2017;8(5):495–511.
10. Longo DL, et al. Harrison's Principles of Internal Medicine. 21st ed. McGraw-Hill; 2022.
11. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. NLRP3 inflammasome activation in gout. Nature. 2006;440(7081):237–241.
12. Terkeltaub R. Clinical practice: Gout. N Engl J Med. 2003;349(17):1647–1655.
13. Stamp LK, Dalbeth N. Pathogenesis of gout. Rheum Dis Clin North Am. 2014;40(2):185–201.
14. Pascual E, Sivera F, Andrés M. Synovial fluid analysis in gout. Curr Opin Rheumatol. 2011;23(2):161–169.
15. Boericke W. *Pocket Manual of Homoeopathic Materia Medica*. Reprint ed. New Delhi: B Jain Publishers; 2007.
16. Kent JT. *Lectures on Homoeopathic Materia Medica*. New Delhi: B Jain Publishers; 2009.
17. Stuart Close. *The Genius of Homoeopathy*. New Delhi: B Jain Publishers; 2005.
18. Allen HC. *Keynotes & Characteristics with Comparisons*.B Jain Publishers; 2008.
19. Roberts HA. *The Principles and Art of Cure by Homoeopathy*. New Delhi: B Jain Publishers; 2006.
20. Clarke JH. *A Dictionary of Practical Materia Medica*. New Delhi: B Jain Publishers; 2003.
21. Hahnemann S. *Materia Medica Pura*. New Delhi: B Jain Publishers; 2001.
22. Banerjea SK. *Miasmatic Prescribing*. New Delhi: B Jain Publishers; 2004.
23. Murphy R. *Lotus Materia Medica*. New Delhi: B Jain Publishers; 2012.

ISSN 2347-2251
www.iajpb.org

Vol. 24, Issue 1, 2026

24. Phatak SR. *Materia Medica of Homoeopathic Medicines*. B Jain Publishers; 2005.